United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its position in United Therapeutics Co. (NASDAQ:UTHR) by 7.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,961 shares of the biotechnology company’s stock after selling 1,535 shares during the quarter. Nisa Investment Advisors LLC’s holdings in United Therapeutics were worth $1,558,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Gravity Wealth Inc. acquired a new stake in shares of United Therapeutics in the first quarter valued at $46,000. Quadrant Capital Group LLC grew its stake in shares of United Therapeutics by 552.0% in the first quarter. Quadrant Capital Group LLC now owns 489 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 414 shares in the last quarter. Signaturefd LLC grew its stake in shares of United Therapeutics by 42.0% in the first quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 236 shares in the last quarter. First Hawaiian Bank grew its stake in shares of United Therapeutics by 313.8% in the first quarter. First Hawaiian Bank now owns 1,200 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 910 shares in the last quarter. Finally, Unison Advisors LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at $205,000. 95.37% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently commented on the company. BidaskClub raised United Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday. UBS Group raised United Therapeutics from a “sell” rating to a “neutral” rating and lowered their target price for the stock from $115.00 to $94.00 in a research note on Friday, May 17th. They noted that the move was a valuation call. Cowen reissued a “hold” rating and set a $103.00 target price on shares of United Therapeutics in a research note on Wednesday, May 1st. Credit Suisse Group raised United Therapeutics from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $98.00 to $101.00 in a research note on Monday, July 1st. Finally, LADENBURG THALM/SH SH raised United Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $103.00 to $106.00 in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $123.80.

NASDAQ UTHR traded up $0.19 during trading on Friday, reaching $83.26. 445,907 shares of the company’s stock were exchanged, compared to its average volume of 495,083. The firm has a market cap of $3.47 billion, a PE ratio of 6.22 and a beta of 1.05. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.84 and a current ratio of 7.19. The stock has a 50 day simple moving average of $78.16. United Therapeutics Co. has a 1 year low of $74.31 and a 1 year high of $130.00.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.64 by ($13.96). The business had revenue of $362.70 million for the quarter, compared to analysts’ expectations of $335.72 million. United Therapeutics had a negative return on equity of 4.53% and a negative net margin of 7.69%. The firm’s quarterly revenue was down 6.8% on a year-over-year basis. During the same period last year, the firm earned $3.76 earnings per share. As a group, research analysts anticipate that United Therapeutics Co. will post -5.03 earnings per share for the current fiscal year.

In other United Therapeutics news, Director Raymond Dwek sold 3,750 shares of United Therapeutics stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $76.11, for a total transaction of $285,412.50. Following the completion of the sale, the director now directly owns 3,750 shares of the company’s stock, valued at approximately $285,412.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard Giltner sold 5,000 shares of United Therapeutics stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $79.05, for a total value of $395,250.00. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $395,250. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Read More: What are popular green investing opportunities?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.